P43 Relationship Between the Expression of pdl1 and the Tumor Infiltrating Lymphocytes in Patients with Advanced Lung Cancer

Several studies show that those patients with a PD-L1 expression have greater benefits in the response rate, PFS and OS. In our institution, in 2014, we conducted a study in which it was possible to show that the presence of infiltrating lymphocytes of the tumor is associated with a longer PFS and OS. In another study, we showed that the presence of lymphocyte infiltration, in patients with breast cancer had higher survival; that is why in this study we want to analyze the relationship between the expression of the PD-L1 and the tils. Objective: The objective of this study is to analyze the relationship between the expression of PD-L1 and the intratumoral and stromal TILS in patients with advanced lung cancer and the overall survival of these patients Retrospective and analytical study in which patients with advance NSCLC from Instituto Oncológico de Córdoba were studied. The tumor samples have been analyzed. Immunohistochemistry will be the procedure used to evaluate the expression of PD-L1 and intratumoral and stromal lymphocytes. The survival analysis will be evaluated by the Kaplan-Meier method and by the log-rank test. We analyzed 46 patients, 34 men and 12 women. Out of those patients studied, 26 pts. (56%) had TILSi in their tumor samples, 20 pts. (43.47%) absence of TILS i. Regarding TILSs, 34 pts (73%) showed infiltrate in the sample and 12 pts. (26%) did not present TILSs. Out of those 46 samples analyzed, 22 pts. (48%) showed expression of PD-L1, and 4 pts. (52 %) did not express PD-L1. Patients who presented TILSi had a median OS of 11.4 m vs 8.7 m in those without TILSi, these differences were statistically significant and were related to the expression of PD-L1 p: (0.01 vs 0.4) respectively. Those that evidenced TILs vs absence of TILs. the OS was 11.7 m vs 7.5 m; these differences were significant and were also related to the expression of PD-L1 (0.03 vs 0.1) respectively. We were able to conclude that those patients with NSCLC who had TILi and TILSs, and who also had expression of PD-L1 in their tumor samples, had higher OS than those patients who did not have TILS or expression of PD-L1. This was statistically significant